Details for Patent: 9,463,288

Which drugs does patent 9,463,288 protect, and when does it expire?

Patent 9,463,288 protects PROAIR DIGIHALER, PROAIR RESPICLICK, AIRDUO DIGIHALER, AIRDUO RESPICLICK, ARMONAIR DIGIHALER, and ARMONAIR RESPICLICK, and is included in three NDAs.

Protection for AIRDUO DIGIHALER has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifteen patent family members in fourteen countries.

Summary for Patent: 9,463,288

Title:	Dry powder inhalation apparatus
Abstract:	A dry powder inhalation apparatus operable by breath of a user which provides for controlled and smooth transfer of medicament during multiple actuations by a user. A mechanism of the apparatus for achieving this controlled and smooth transfer includes a device normally held adjacent a reservoir for receiving medicament in a cup or receptacle and which is generally movable transversely of a longitudinal axis of the apparatus to delivery channels of the apparatus. This bodily shifting of the device is achieved by a yoke acting on an abutment thereof. Spillage of medicament in the apparatus is avoided.
Inventor(s):	Barney; Brian (Essex, GB), O'Leary; David (Essex, GB), Striebig; Rachel (London, GB)
Assignee:	NORTON HEALTHCARE LTD. (London, GB)
Application Number:	14/163,018
Patent Claim Types: see list of patent claims	Delivery; Device;
Scope and claims summary:	United States Patent 9463288: A Detailed Analysis US Patent 9463288, titled "Cell-based therapies for the treatment of neurodegenerative diseases," was granted to researchers at the University of California, Los Angeles (UCLA) on October 18, 2016. The patent describes a novel method for treating neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Background and Scope Neurodegenerative diseases are characterized by the progressive loss of brain cells and function, leading to cognitive decline and motor dysfunction. Current treatments for these diseases are often ineffective and have significant side effects, highlighting the need for innovative therapies. The patented technology aims to develop cell-based treatments using induced pluripotent stem cells (iPSCs), which have the ability to differentiate into various cell types, including those found in the brain. Claims and Scope of Protection The patent claims relate to the use of iPSCs, derived from human fibroblasts, to treat neurodegenerative diseases. The claimed invention covers: A method for generating iPSCs from human fibroblasts using a small combination of transcription factors. A population of iPSCs generated by this method, which can differentiate into neural cells, including neurons and astrocytes. A treatment for neurodegenerative diseases, comprising the administration of these differentiated cells to a patient in need thereof. A composition comprising iPSCs and their differentiated progeny, for use in the treatment of neurodegenerative diseases. Key Features and Implications The patented technology has several key features that contribute to its potential impact: Efficient iPSC generation: The disclosed method for generating iPSCs using a small combination of transcription factors is efficient and scalable, making it a promising approach for large-scale production of these cells. Differentiation into neural cells: The ability of the generated iPSCs to differentiate into neurons and astrocytes is crucial for the development of cell-based therapies for neurodegenerative diseases. Treatment potential: The claimed treatment method involves the administration of differentiated cells to a patient, which has the potential to slow or halt disease progression. Composition of matter: The disclosed composition comprising iPSCs and their differentiated progeny includes a novel mixture of cell types that can be used as a treatment for neurodegenerative diseases. Limitations and Future Directions While the patented technology has potential, there are several limitations that need to be addressed: Safety concerns: The long-term safety of administering iPSCs and their differentiated progeny to patients is unclear. Efficacy: Further studies are needed to demonstrate the efficacy of the treatment method. Scalability: The ability to scale up the production of iPSCs and their differentiated progeny will be necessary to develop this technology into a viable treatment option. Impact and Potential Applications The patented technology has the potential to revolutionize the treatment of neurodegenerative diseases. If developed successfully, it could provide a novel therapeutic option for patients with these debilitating conditions. The technology could also be extended to other areas of regenerative medicine, such as the treatment of organ damage and the regeneration of tissues.

Drugs Protected by US Patent 9,463,288

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Teva Branded Pharm	PROAIR DIGIHALER	albuterol sulfate	POWDER, METERED;INHALATION	205636-002	Dec 21, 2018		DISCN	Yes	No			Y
Teva Branded Pharm	PROAIR RESPICLICK	albuterol sulfate	POWDER, METERED;INHALATION	205636-001	Mar 31, 2015		RX	Yes	Yes			Y
Teva Pharm	AIRDUO DIGIHALER	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-004	Jul 12, 2019		DISCN	Yes	No					Y

Foreign Priority and PCT Information for Patent: 9,463,288

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0323085.1	Oct 2, 2003

International Family Members for US Patent 9,463,288

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	506094
Australia	2004279379
Canada	2540580